ZOPICLONE, SLEEP AND HEALTH-RELATED QUALITY-OF-LIFE

458 insomniac patients participated in a multinational, randomised, do uble blind, parallel groups study of zopiclone 7.5 mg versus placebo. Patients received the drug or placebo nightly for 14 days and for a fu rther six weeks on demand. Sleep characteristics and Quality of Life m easures were assessed at 14, 28 and 56 days after admission. Both grou ps of patients improved on these measures, but the active treatment sh owed significantly greater improvement compared to placebo, both after 14 days and at the end of the trial.